Company news

ImmuneOnco Announced That Its CHOK1-GSKO Cell Line Successfully Passed The Quality Verification

2017-1-12 0:00:00Click:891

    On January 12 of 2017, ImmuneOnco Biopharmaceuticals Co., Ltd., an emerging biotech company fully focusing on discovery and development of tumor immunotherapy, announced that, they have successfully knocked out the glutamine synthetase (GS) gene from a suspension-cultured CHO-K1 cell line. The resulting cell line (CHOK1-GSKO) was contracted out to China Center for Type Culture Collection (CCTCC) for quality verification. Recently, they received the verification report concluding that “The CHOK1-GSKO cell bank (Lot# 20160923) developed by ImmuneOnco Biopharmaceuticals Co., Ltd successfully passed the quality verification analysis, all parameters meet the criteria set by “Pharmacopoeia of People's Republic of China, 3rd version of 2015”.
   The CHOK1-GSKO cell can be used for quick screening and development of antibody-like protein expressing stable cell line. The screening time can be shortened to 3-4 months since gene electroporation.